145 - 156 of 7642 results

FAQ for To Be or Not to Be Gluten Free: Food Elimination Diets for Allergies, Intolerances and Wellness

Increasing numbers of patients are talking with their health care professionals about specialized diets and testing for allergies and food sensitivities as part of their overall wellness plan. Good diet quality is a well-recognized element of lifestyle medicine, but there is growing confusion among medical professionals and consumers about "good" foods and if they should eliminate certain foods from their diet. This talk will cover several of the popular media approaches to healthy living, including diets like Gluten Free, Whole 30, Ketogenic, as well as relevant data for health-related outcomes for each. The differences between allergic bowel disorders and intolerances will be discussed. Clinical and nutritional counseling tips will be provided.Guest: Bethany Doerfler, MS, RDN

Increasing numbers of patients are talking with their health care professionals about specialized diets and testing for allergies and food sensitivities as part of their overall wellness plan. Good diet quality is a well-recognized element of lifestyle medicine, but there is growing confusion among medical professionals and consumers about "good" foods and if they should eliminate certain foods from their diet. This talk will cover several of the popular media approaches to healthy living, including diets like Gluten Free, Whole 30, Ketogenic, as well as relevant data for health-related outcomes for each. The differences between allergic bowel disorders and intolerances will be discussed. Clinical and nutritional counseling tips will be provided.


COVID-19: What Do We Know Now?

Industry Podcast Sponsored by GlaxoSmithKline; Not for CME/CE Credit


FAQ for the Pharmacotherapy of Alcohol and Opioid Use Disorders

In the U.S., about 15.1 million people have an alcohol use disorder and about 4.8 million misuse opioids. This session focuses on the pharmacotherapy of alcohol and opioid use disorders. The faculty will describe and contrast naltrexone and acamprosate treatments for alcohol use disorder and discuss the use of buprenorphine/naloxone to treat opioid use disorder.Guest: Petros Levounis, MD, MA

In the U.S., about 15.1 million people have an alcohol use disorder and about 4.8 million misuse opioids. This session focuses on the pharmacotherapy of alcohol and opioid use disorders. The faculty will describe and contrast naltrexone and acamprosate treatments for alcohol use disorder and discuss the use of buprenorphine/naloxone to treat opioid use disorder.


This presentation will hone in on the practical overlap between psychiatry and medicine in diagnosis and treatment. The speaker will cover (1) the interview, establishing rapport, and the efficient use of time; (2) major areas of psychiatric dysfunction and how they interact with other aspects of health; (3) differential diagnosis of anxiety, psychosis, depression, mood instability, and cognitive problems; (4) behavioral risk, especially suicide; and (5) pharmacological and nonpharmacological treatments.


FAQ for Fad Diets: Keto, Elimination, and More

Guest: Bethany Doerfler, MS, RDN


Infectious diseases syndromes are common in primary care practices. However, staying current with relevant literature that may influence appropriate evaluation and treatment of patients with these syndromes can be difficult, given the volumes of applicable articles and diversity of journals publishing these reports. This session will present some common infectious disease scenarios and provide crucial literature updates. You will learn about how responding to histories of penicillin allergy may result in adverse patient outcomes, the proper timing of influenza vaccination, the influence of substance abuse on risk medication adherence and infectious diseases risk, the appropriate evaluation of patients with suspected cellulitis syndromes, and the role of preoperative urine screening.


FAQ for GAIT: An Eyeblink Diagnosis

Guest: Salvatore Mangione, MD

Mobility disorders are a menace of old age, often resulting in falls, injuries, and especially hip fractures -- the sixth leading cause of death in the elderly. Primary care physicians have difficulties in both detecting and correctly identifying these abnormalities. In a paper published in the Journal of the American Geriatrics Society in 2004 [52(9):1527-31], the authors concluded that "community physicians appear to underdetect falls and gait disorders, leading to a paucity of recommendations and treatments." Hence the need to revisit the most common gait abnormalities. This multimedia presentation will provide a panorama of bipedalism, from its origin six million years ago in the savannahs of East Africa, to its rise as the unique trait of our species, and eventually to its status as a major cause of disability once full bipedalism is lost. The talk will review the physiology of ambulation and the prevalence of gait disorders in the population. In addition to detailed information on psychogenic and antalgic gaits, participants will learn about the seven major gait abnormalities. Whenever possible, the speaker will enliven the delivery by reviewing "famous patients," or vignettes of historical figures and celebrities who suffered the disorder.


Living in a World with COVID-19: From Reaction to Action

Industry Podcast Sponsored by GlaxoSmithKline; Not for CME/CE Credit


In this informative session, the speaker will help clinicians build better understandings with their patients and discuss how to make the office a more welcoming environment. Participants will walk away with culturally informed and sensitive approaches to counseling and an enhanced comprehension of the unique mental health problems faced by the LGBTQ population.


Coffee with Chopra: Episode 6
0.5 CME CREDIT

Are opioids effective in chronic pain management? Join neurologist and pain specialist, Dr. Charles Argoff, as he summarizes two recent trials published in JAMA examining the efficacy of opioids in pain management and discusses their clinical implications. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA). Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 11/23/2020 and they are subject to change as new information is published.